HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling = HSP90 alpha

Background Tumor cells modulate host immunity by secreting extracellular vesicles (EV) and soluble factors. Their interactions with myeloid cells lead to the generation of myeloid-derived suppressor cells (MDSC), which inhibit the antitumor function of T and NK cells. We demonstrated previously that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Arkhypov, Ihor (VerfasserIn) , Özbay Kurt, Feyza Gül (VerfasserIn) , Bitsch, Rebekka (VerfasserIn) , Novak, Daniel (VerfasserIn) , Petrova, Vera (VerfasserIn) , Lasser, Samantha (VerfasserIn) , Hielscher, Thomas (VerfasserIn) , Groth, Christopher (VerfasserIn) , Lepper, Alisa (VerfasserIn) , Hu, Xiaoying (VerfasserIn) , Li, Wei (VerfasserIn) , Utikal, Jochen (VerfasserIn) , Altevogt, Peter (VerfasserIn) , Umansky, Viktor (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 16 September 2022
In: Journal for ImmunoTherapy of Cancer
Year: 2022, Jahrgang: 10, Heft: 9, Pages: 1-12
ISSN:2051-1426
DOI:10.1136/jitc-2022-005551
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/jitc-2022-005551
Verlag, kostenfrei, Volltext: http://jitc.bmj.com/content/10/9/e005551
Volltext
Verfasserangaben:Ihor Arkhypov, Feyza Gül Özbay Kurt, Rebekka Bitsch, Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, Alisa Lepper, Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky

MARC

LEADER 00000caa a2200000 c 4500
001 1859807682
003 DE-627
005 20240307084247.0
007 cr uuu---uuuuu
008 230918s2022 xx |||||o 00| ||eng c
024 7 |a 10.1136/jitc-2022-005551  |2 doi 
035 |a (DE-627)1859807682 
035 |a (DE-599)KXP1859807682 
035 |a (OCoLC)1425216868 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Arkhypov, Ihor  |d 1995-  |e VerfasserIn  |0 (DE-588)122727694X  |0 (DE-627)1748337882  |4 aut 
245 1 0 |a HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling  |b  = HSP90 alpha  |c Ihor Arkhypov, Feyza Gül Özbay Kurt, Rebekka Bitsch, Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, Alisa Lepper, Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky 
246 3 1 |a HSP90 alpha 
246 3 3 |a HSP90alpha induces immunosuppressive myeloid cells in melanoma via TLRfour signaling 
264 1 |c 16 September 2022 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Zusätzliches ergänzendes Material wird nur online veröffentlicht 
500 |a Gesehen am 18.09.2023 
520 |a Background Tumor cells modulate host immunity by secreting extracellular vesicles (EV) and soluble factors. Their interactions with myeloid cells lead to the generation of myeloid-derived suppressor cells (MDSC), which inhibit the antitumor function of T and NK cells. We demonstrated previously that EV derived from mouse and human melanoma cells induced immunosuppressive activity via increased expression of programmed cell death ligand 1 (PD-L1) on myeloid cells that was dependent on the heat-shock protein 90α (HSP90α) in EV. Here, we investigated whether soluble HSP90α could convert monocytes into MDSC. - Methods CD14 monocytes were isolated from the peripheral blood of healthy donors, incubated with human recombinant HSP90α (rHSP90α) alone or in the presence of inhibitors of TLR4 signaling and analyzed by flow cytometry. Inhibition of T cell proliferation assay was applied to assess the immunosuppressive function of rHSP90α-treated monocytes. HSP90α levels were measured by ELISA in plasma of patients with advanced melanoma and correlated with clinical outcome. - Results We found that the incubation of monocytes with rHSP90α resulted in a strong upregulation of PD-L1 expression, whereas reactive oxygen species (ROS) and nitric oxide (NO) production as well as the expression of arginase-1, ectoenzymes CD39 and CD73 remained unchanged. The PD-L1 upregulation was blocked by anti-TLR4 antibodies and a nuclear factor-κB inhibitor. rHSP90α-treated monocytes displayed the downregulation of HLA-DR expression and acquired the resistance to apoptosis. Moreover, these monocytes were converted into MDSC as indicated by their capacity to inhibit T cell proliferation, which was mediated by TLR4 signaling as well as PD-L1 and indoleamine 2,3-dioxygenase (IDO) 1 expression. Higher levels of HSP90α in plasma of patients with melanoma correlated with augmented PD-L1 expression on circulating monocytic (M)-MDSC. Patients with melanoma with high levels of HSP90α displayed shorter progression-free survival (PFS) on the treatment with immune checkpoint inhibitors (ICIs). - Conclusion Our findings demonstrated that soluble rHSP90α increased the resistance of normal human monocytes to apoptosis and converted them into immunosuppressive MDSC via TLR4 signaling that stimulated PD-L1 and IDO-1 expression. Furthermore, patients with melanoma with high concentrations of HSP90α displayed increased PD-L1 expression on M-MDSC and reduced PFS after ICI therapy, suggesting HSP90α as a promising therapeutic target for overcoming immunosuppression in melanoma. 
650 4 |a Melanoma 
650 4 |a Myeloid-Derived Suppressor Cells 
650 4 |a Tumor Escape 
650 4 |a Tumor Microenvironment 
700 1 |a Özbay Kurt, Feyza Gül  |d 1992-  |e VerfasserIn  |0 (DE-588)1284914275  |0 (DE-627)1840611251  |4 aut 
700 1 |a Bitsch, Rebekka  |d 1991-  |e VerfasserIn  |0 (DE-588)1163544582  |0 (DE-627)1027872069  |0 (DE-576)508043565  |4 aut 
700 1 |a Novak, Daniel  |d 1978-  |e VerfasserIn  |0 (DE-588)1026462975  |0 (DE-627)726763764  |0 (DE-576)371815533  |4 aut 
700 1 |a Petrova, Vera  |d 1995-  |e VerfasserIn  |0 (DE-588)1227277474  |0 (DE-627)1748338692  |4 aut 
700 1 |a Lasser, Samantha  |d 1990-  |e VerfasserIn  |0 (DE-588)1227276850  |0 (DE-627)174833753X  |4 aut 
700 1 |a Hielscher, Thomas  |e VerfasserIn  |0 (DE-588)1159594791  |0 (DE-627)1022977768  |0 (DE-576)50506068X  |4 aut 
700 1 |a Groth, Christopher  |d 1989-2025  |e VerfasserIn  |0 (DE-588)1156675456  |0 (DE-627)1019506482  |0 (DE-576)502360151  |4 aut 
700 1 |a Lepper, Alisa  |d 1998-  |e VerfasserIn  |0 (DE-588)1299246060  |0 (DE-627)1856129756  |4 aut 
700 1 |a Hu, Xiaoying  |d 1990-  |e VerfasserIn  |0 (DE-588)1188900889  |0 (DE-627)1667767593  |4 aut 
700 1 |a Li, Wei  |e VerfasserIn  |4 aut 
700 1 |a Utikal, Jochen  |d 1974-  |e VerfasserIn  |0 (DE-588)1026463750  |0 (DE-627)726765015  |0 (DE-576)371816580  |4 aut 
700 1 |a Altevogt, Peter  |d 1947-  |e VerfasserIn  |0 (DE-588)1113206306  |0 (DE-627)867118784  |0 (DE-576)164729240  |4 aut 
700 1 |a Umansky, Viktor  |d 1955-  |e VerfasserIn  |0 (DE-588)102885756X  |0 (DE-627)731733207  |0 (DE-576)376300078  |4 aut 
773 0 8 |i Enthalten in  |t Journal for ImmunoTherapy of Cancer  |d London : BioMed Central, 2013  |g 10(2022), 9, Artikel-ID e005551, Seite 1-12  |h Online-Ressource  |w (DE-627)750086335  |w (DE-600)2719863-7  |w (DE-576)383767369  |x 2051-1426  |7 nnas  |a HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling = HSP90 alpha 
773 1 8 |g volume:10  |g year:2022  |g number:9  |g elocationid:e005551  |g pages:1-12  |g extent:12  |a HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling = HSP90 alpha 
856 4 0 |u https://doi.org/10.1136/jitc-2022-005551  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://jitc.bmj.com/content/10/9/e005551  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20230918 
993 |a Article 
994 |a 2022 
998 |g 102885756X  |a Umansky, Viktor  |m 102885756X:Umansky, Viktor  |d 60000  |d 61900  |d 140000  |e 60000PU102885756X  |e 61900PU102885756X  |e 140000PU102885756X  |k 0/60000/  |k 1/60000/61900/  |k 0/140000/  |p 14  |y j 
998 |g 1113206306  |a Altevogt, Peter  |m 1113206306:Altevogt, Peter  |d 60000  |d 61900  |d 50000  |e 60000PA1113206306  |e 61900PA1113206306  |e 50000PA1113206306  |k 0/60000/  |k 1/60000/61900/  |k 0/50000/  |p 13 
998 |g 1026463750  |a Utikal, Jochen  |m 1026463750:Utikal, Jochen  |d 60000  |e 60000PU1026463750  |k 0/60000/  |p 12 
998 |g 1188900889  |a Hu, Xiaoying  |m 1188900889:Hu, Xiaoying  |p 10 
998 |g 1299246060  |a Lepper, Alisa  |m 1299246060:Lepper, Alisa  |d 60000  |e 60000PL1299246060  |k 0/60000/  |p 9 
998 |g 1156675456  |a Groth, Christopher  |m 1156675456:Groth, Christopher  |d 60000  |d 61900  |d 60000  |d 65400  |e 60000PG1156675456  |e 61900PG1156675456  |e 60000PG1156675456  |e 65400PG1156675456  |k 0/60000/  |k 1/60000/61900/  |k 0/60000/  |k 1/60000/65400/  |p 8 
998 |g 1159594791  |a Hielscher, Thomas  |m 1159594791:Hielscher, Thomas  |d 140000  |e 140000PH1159594791  |k 0/140000/  |p 7 
998 |g 1227276850  |a Lasser, Samantha  |m 1227276850:Lasser, Samantha  |d 60000  |d 61900  |e 60000PL1227276850  |e 61900PL1227276850  |k 0/60000/  |k 1/60000/61900/  |p 6 
998 |g 1227277474  |a Petrova, Vera  |m 1227277474:Petrova, Vera  |d 60000  |e 60000PP1227277474  |k 0/60000/  |p 5 
998 |g 1026462975  |a Novak, Daniel  |m 1026462975:Novak, Daniel  |d 60000  |d 61900  |e 60000PN1026462975  |e 61900PN1026462975  |k 0/60000/  |k 1/60000/61900/  |p 4 
998 |g 1163544582  |a Bitsch, Rebekka  |m 1163544582:Bitsch, Rebekka  |d 60000  |d 61900  |e 60000PB1163544582  |e 61900PB1163544582  |k 0/60000/  |k 1/60000/61900/  |p 3 
998 |g 1284914275  |a Özbay Kurt, Feyza Gül  |m 1284914275:Özbay Kurt, Feyza Gül  |d 140000  |e 140000PO1284914275  |k 0/140000/  |p 2 
998 |g 122727694X  |a Arkhypov, Ihor  |m 122727694X:Arkhypov, Ihor  |d 60000  |d 61900  |e 60000PA122727694X  |e 61900PA122727694X  |k 0/60000/  |k 1/60000/61900/  |p 1  |x j 
999 |a KXP-PPN1859807682  |e 4377378775 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"part":{"text":"10(2022), 9, Artikel-ID e005551, Seite 1-12","volume":"10","year":"2022","pages":"1-12","issue":"9","extent":"12"},"title":[{"subtitle":"official journal of the Society for Immunotherapy of Cancer (SITC)","title_sort":"Journal for ImmunoTherapy of Cancer","title":"Journal for ImmunoTherapy of Cancer"}],"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["2051-1426"],"zdb":["2719863-7"],"eki":["750086335"]},"recId":"750086335","origin":[{"dateIssuedKey":"2013","publisherPlace":"London","dateIssuedDisp":"2013-","publisher":"BioMed Central"}],"disp":"HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling = HSP90 alphaJournal for ImmunoTherapy of Cancer","language":["eng"],"pubHistory":["1.2013 -"],"note":["Gesehen am 29.06.20"]}],"physDesc":[{"extent":"12 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1859807682","titleTranslated":[{"translated":"HSP90 alpha"}],"name":{"displayForm":["Ihor Arkhypov, Feyza Gül Özbay Kurt, Rebekka Bitsch, Daniel Novak, Vera Petrova, Samantha Lasser, Thomas Hielscher, Christopher Groth, Alisa Lepper, Xiaoying Hu, Wei Li, Jochen Utikal, Peter Altevogt, Viktor Umansky"]},"title":[{"title":"HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling","subtitle":" = HSP90 alpha","title_sort":"HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling"}],"note":["Zusätzliches ergänzendes Material wird nur online veröffentlicht","Gesehen am 18.09.2023"],"titleAlt":[{"title":"HSP90alpha induces immunosuppressive myeloid cells in melanoma via TLRfour signaling"}],"person":[{"display":"Arkhypov, Ihor","role":"aut","family":"Arkhypov","given":"Ihor"},{"given":"Feyza Gül","role":"aut","family":"Özbay Kurt","display":"Özbay Kurt, Feyza Gül"},{"role":"aut","family":"Bitsch","display":"Bitsch, Rebekka","given":"Rebekka"},{"given":"Daniel","display":"Novak, Daniel","family":"Novak","role":"aut"},{"given":"Vera","family":"Petrova","role":"aut","display":"Petrova, Vera"},{"given":"Samantha","display":"Lasser, Samantha","family":"Lasser","role":"aut"},{"given":"Thomas","display":"Hielscher, Thomas","family":"Hielscher","role":"aut"},{"given":"Christopher","family":"Groth","role":"aut","display":"Groth, Christopher"},{"role":"aut","family":"Lepper","display":"Lepper, Alisa","given":"Alisa"},{"given":"Xiaoying","display":"Hu, Xiaoying","role":"aut","family":"Hu"},{"given":"Wei","display":"Li, Wei","role":"aut","family":"Li"},{"display":"Utikal, Jochen","role":"aut","family":"Utikal","given":"Jochen"},{"display":"Altevogt, Peter","family":"Altevogt","role":"aut","given":"Peter"},{"given":"Viktor","display":"Umansky, Viktor","role":"aut","family":"Umansky"}],"id":{"eki":["1859807682"],"doi":["10.1136/jitc-2022-005551"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"16 September 2022"}]} 
SRT |a ARKHYPOVIHHSP90INDUC1620